AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 7, 2005, Pages 4366-4370

  Fassnacht, Martin ^a   Weismann, Dirk ^a   Ebert, Silke ^a   Adam, Patrick ^a   Zink, Martina ^a   Beuschlein, Felix ^b   Hahner, Stefanie ^a   Allolio, Bruno ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; HYDROCORTISONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL GLAND; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OUTCOMES RESEARCH; PATHOGENESIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

EID: 23044465986     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2004-2198     Document Type: Article

References (42)

1. Maher ER, Eng C 2002 The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 11:2347-2354
2. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459-1466
3. Datta SR, Brunet A, Greenberg ME 1999 Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
4. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
5. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M 2004 PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30:193-204
6. Terakawa N, Kanamori Y, Yoshida S 2003 Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10:203-208
7. David O 2001 Akt and PTEN: new diagnostic markers of non-small cell lung cancer? J Cell Mol Med 5:430-433
8. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947
9. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L, DePinho RA 2002 Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99:1455-1460
10. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW 2000 High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten +/- mice. Cancer Res 60:3605-3611
11. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, Carrera AC, Landazuri MO, del Peso L 2001 Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells. protective role in apoptosis. J Biol Chem 276:22368-22374
12. Viard I, Jaillard C, Saez JM 1993 Regulation by growth factors (IGF-I, b-FGF and TGF-β) of proto-oncogene mRNA, growth and differentiation of bovine adrenocortical fasciculata cells. FEBS Lett 328:94-98
13. Reincke M 1998 Mutations in adrenocortical tumors. Horm Metab Res 30:447-455
14. Kirschner LS 2002 Signaling pathways in adrenocortical cancer. Ann NY Acad Sci 968:222-239
15. Koch CA, Pacak K, Chrousos GP 2002 The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87:5367-5384
16. Boulle N, Gicquel C, Logie A, Christol R, Feige JJ, Le Bouc Y 2000 Fibroblast growth factor-2 inhibits the maturation of pro-insulin-like growth factor-II (Pro-IGF-II) and the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in the human adrenocortical tumor cell line NCI-H295R. Endocrinology 141:3127-3136
17. Ohgaki H, Kleihues P, Heitz PU 1993 p53 mutations in sporadic adrenocortical tumors. Int J Cancer 54:408-410
18. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, Chrousos GP 1994 p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78:790-794
19. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D 1994 High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707-1710
20. Kjellman M, Larsson C, Backdahl M 2001 Genetic background of adrenocortical tumor development. World J Surg 25:948-956
21. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531
22. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
23. Fassnacht M, Hahner S, Hansen IA, Kreutzberger T, Zink M, Adermann K, Jakob F, Troppmair J, Allolio B 2003 N-terminal proopiomelanocortin acts as a mitogen in adrenocortical tumor cells and decreases adrenal steroidogenesis. J Clin Endocrinol Metab 88:2171-2179
24. Zhou XP, Marsh DJ, Morrison CD, Chaudhury AR, Maxwell M, Reifenberger G, Eng C 2003 Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 73:1191-1198
25. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K 2004 Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 10:2846-2850
26. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C 2000 Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 157:1123-1128
27. Zhou XP, Loukola A, Salovaara R, Nystrom-Lahti M, Peltomaki P, de la Chapelle A, Aaltonen LA, Eng C 2002 PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161:439-447
28. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H 1999 The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96:10182-10187
29. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL 1998 Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246-5250
30. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP 2003 Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 63:2881-2890
31. Eng C 2002 Role of PTEN, a lipid phosphatase upstream effector of protein kinase B, in epithelial thyroid carcinogenesis. Ann NY Acad Sci 968:213-221.
32. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ 2001 AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431-437
33. Segouffin-Cariou C, Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 275:3568-3576
34. De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M 2000 Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 60:3727-3731
35. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA 2003 Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590-603
36. Bjornsti MA, Houghton PJ 2004 The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348
37. Manning BD 2004 Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167:399-403
38. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241
39. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI 2002 Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171
40. Shi W, Zhang X, Pintilie M, Ma N, Miller N, Banerjee D, Tsao MS, Mak T, Fyles A, Liu FF 2003 Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104:195-203
41. Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, Rutqvist LE 2003 Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 5:R37-R44
42. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y 2002 Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 277:33490-33500